iTeos Therapeutics Inc. (ITOS)
6.57
-0.13 (-2.01%)
At close: Mar 28, 2025, 11:53 AM
-2.01% (1D)
| Bid | 6.56 |
| Market Cap | 250.94M |
| Revenue (ttm) | 33.03M |
| Net Income (ttm) | -126.84M |
| EPS (ttm) | -3.32 |
| PE Ratio (ttm) | -1.98 |
| Forward PE | -2.05 |
| Analyst | Buy |
| Ask | 6.62 |
| Volume | 28,715 |
| Avg. Volume (20D) | 319,820 |
| Open | 6.71 |
| Previous Close | 6.71 |
| Day's Range | 6.52 - 6.80 |
| 52-Week Range | 6.32 - 18.75 |
| Beta | 1.38 |
About ITOS
Iteos Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery and development of immuno-oncology therapeutics for patients. The company's product pipeline includes inupadenant, a small molecule antagonist of the adenosine A2AR antagonists that is in Phase 2 clinical trials; and EOS-448, an antagonist of TIGIT or T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1/2 clinical trial, as well as used t...
Industry Biotechnology
Sector Healthcare
IPO Date Jul 24, 2020
Employees 173
Stock Exchange NASDAQ
Ticker Symbol ITOS
Analyst Forecast
According to 3 analyst ratings, the average rating for ITOS stock is "Buy." The 12-month stock price forecast is $17, which is an increase of 158.75% from the latest price.
Stock Forecasts6 months ago
-27.54%
iTeos Therapeutics shares are trading lower. The c...
Unlock content with
Pro Subscription
7 months ago
+10.13%
iTeos Therapeutics shares are trading higher after the company announced the oral presentation of Phase 2 GALAXIES Lung-201 interim data at the European Society for Medical Oncology Congress 2024
